[Auto-inflammatory reaction triggered by Nivolumab: A case of adult-onset Still's disease-like syndrome]

Stéphanie Hermabessière; Pascale Palassin; Xavier Quantin; Alexandre T J Maria; Cyrille Coustal

doi:10.1016/j.bulcan.2024.05.009

[Auto-inflammatory reaction triggered by Nivolumab: A case of adult-onset Still's disease-like syndrome]

Bull Cancer. 2024 Oct;111(10):989-991. doi: 10.1016/j.bulcan.2024.05.009. Epub 2024 Sep 10.

[Article in French]

Authors

Stéphanie Hermabessière¹, Pascale Palassin², Xavier Quantin³, Alexandre T J Maria⁴, Cyrille Coustal⁵

Affiliations

¹ Médecine interne et maladies-multi-organiques, centre de compétences des maladies auto-immunes, CHU de Montpellier, Montpellier, France.
² Pharmacologie médicale et toxicologie, centre régional de pharmacovigilance, CHU de Montpellier, Montpellier, France.
³ Inserm U1194, Institut du cancer de Montpellier (ICM), Institut de recherche du cancer de Montpellier (IRCM), université de Montpellier, Montpellier, France.
⁴ Médecine interne et immuno-oncologie (MedI2O), Institute for Regenerative Medicine and Biotherapy (IRMB), CHU de Montpellier, Montpellier, France.
⁵ Médecine interne et maladies-multi-organiques, centre de compétences des maladies auto-immunes, CHU de Montpellier, Montpellier, France. Electronic address: [email protected].

PMID: 39261249
DOI: 10.1016/j.bulcan.2024.05.009

No abstract available

Keywords: Adult-onset Still's disease; Adénocarcinome pulmonaire; Hemophagocytic lymphohistiocytosis; Hémophagocytose lymphohistiocytaire; Immune checkpoint inhibitors; Inhibiteurs des points de contrôle immunitaires; Maladie de Still de l’adulte; Pulmonary adenocarcinoma.

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Female
Humans
Male
Middle Aged
Nivolumab* / adverse effects
Nivolumab* / therapeutic use
Still's Disease, Adult-Onset* / drug therapy

Substances

Nivolumab
Antineoplastic Agents, Immunological